Search results
Results from the WOW.Com Content Network
An article published by the journal Nature on 6 July 2021 cited data released by the United Arab Emirates on some 81,000 individuals who had received Sputnik V, according to which the vaccine demonstrated an efficacy of 97.8% in preventing symptomatic COVID-19, and 100% efficacy in preventing severe complications.
A vaccine is generally considered effective if the estimate is ≥50% with a >30% lower limit of the 95% confidence interval. [6] As of September 2021, no study on Sputnik Light reported confidence intervals, so it is not possible to know the accuracy of the estimates. Effectiveness is generally expected to slowly decrease over time. [7]
Retrospective cohort study of the effectiveness of two Russian vaccines against the SARS-CoV-2 Delta variant in Moscow (June–July 2021) proved that EpiVacCorona, unlike Sputnik V, is an ineffective vaccine and therefore cannot protect against COVID-19.
This man may hold the cure to the coronavirus pandemic in his hands. Alexander Gintsburg is the head of the Gamaleya Institute -- the organization that produced Russia's Sputnik V vaccine. Its ...
If you're a healthy adult age 50 or above, you should get vaccinated against shingles, medical experts say. The vaccine they recommend is Shingrix. With its more than 90 percent success in ...
The shingles vaccine is a two-dose series and provides protection for at least seven years, Tonizzo said. “It’s safe in everyone and is 90% to 95% effective.
The South African Health Products Regulatory Authority (SAHPRA) has confirmed that it has received documentation for the vaccine developed by the Gamaleya Institute in Russia. [49] Sputnik V (Gam-COVID-Vac) is one of three Covid vaccines worldwide with an efficacy higher than 90% in
The head of the Russian Direct Investment Fund (RDIF) stated that 20 countries had requested in total 1 billion doses of the vaccine, nicknamed Sputnik V. [11] On August 20 registration was called "conditional" with final registration depends on results of Phase 3 trial, [12] such registration is limited and allowed by Decree 441 for medicines ...